Abstract
While chemo- and radiotherapy is far developed and successfully employed by default for cancer treatment, severe side effects point to the urgent need for more specific therapies based on the molecular mechanisms of this disease. Strategies to specifically inhibit signaling pathways that are known to force proliferation, prevent apoptosis or promote angiogenesis are expected to have a substantial impact on the future direction taken in cancer therapy. The Janus Kinase (JAK) / Signal transducer and activator of transcription (STAT) pathway is one major signaling pathway converting the signal of cytokines, growth factors and hormones into gene expression programs regulating essential cellular functions like proliferation, differentiation and survival. The suppressors of cytokine signaling (SOCS) as well as phosphatases normally tightly regulate the JAK/STAT pathway. Frequently, however this pathway is constitutively activated in a wide variety of human malignancies and substantially contributes to carcinogenesis. Consequently, new strategies for targeting the JAK/STAT pathway have been developed. This review discusses the biology of the JAK/STAT signaling pathway, which offers several molecular strategies for therapeutic interruption.
Keywords: STAT, JAK, cancer, cytokine, SOCS, signaling, inhibitors
Current Signal Transduction Therapy
Title: Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy
Volume: 1 Issue: 3
Author(s): Edith Pfitzner, Frank Nonnenmacher and Daniela Baus
Affiliation:
Keywords: STAT, JAK, cancer, cytokine, SOCS, signaling, inhibitors
Abstract: While chemo- and radiotherapy is far developed and successfully employed by default for cancer treatment, severe side effects point to the urgent need for more specific therapies based on the molecular mechanisms of this disease. Strategies to specifically inhibit signaling pathways that are known to force proliferation, prevent apoptosis or promote angiogenesis are expected to have a substantial impact on the future direction taken in cancer therapy. The Janus Kinase (JAK) / Signal transducer and activator of transcription (STAT) pathway is one major signaling pathway converting the signal of cytokines, growth factors and hormones into gene expression programs regulating essential cellular functions like proliferation, differentiation and survival. The suppressors of cytokine signaling (SOCS) as well as phosphatases normally tightly regulate the JAK/STAT pathway. Frequently, however this pathway is constitutively activated in a wide variety of human malignancies and substantially contributes to carcinogenesis. Consequently, new strategies for targeting the JAK/STAT pathway have been developed. This review discusses the biology of the JAK/STAT signaling pathway, which offers several molecular strategies for therapeutic interruption.
Export Options
About this article
Cite this article as:
Pfitzner Edith, Nonnenmacher Frank and Baus Daniela, Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy, Current Signal Transduction Therapy 2006; 1 (3) . https://dx.doi.org/10.2174/157436206778226914
DOI https://dx.doi.org/10.2174/157436206778226914 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Profiles of Sentinel and Non-Sentinel Lymph Nodes in Breast Cancer Progression and Prognosis
Current Cancer Therapy Reviews The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality
Current Cancer Drug Targets Immune Stimulatory Strategies for the Prevention and Treatment of Asthma
Current Pharmaceutical Design Ligand-Targeted Liposomes for Cancer Treatment
Current Drug Delivery Image Fusion of Diagnostic Ultrasound with Other Modalities
Current Medical Imaging Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry STAT Inhibition in the Treatment of Cancer: Transcription Factors as Targets for Molecular Therapy
Current Cancer Therapy Reviews Formulation Development and Evaluation of Transdermal 5-Fluorouracil Ethosomal Formulation through 2<sup>5-2</sup> Fractional Factorial Design
Drug Delivery Letters Alternative Splicing and Tumor Progression
Current Genomics IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Current Medicinal Chemistry Chemosensitization of Prostate Cancer by Modulating Bcl-2 Family Proteins
Current Drug Targets Src Family Nonreceptor Tyrosine Kinases as Molecular Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Amplicons as Vaccine Vectors
Current Gene Therapy HLA-I Antigen Presentation and Tapasin Influence Immune Responses Against Malignant Brain Tumors-Considerations for Successful Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Cancer and Cyclooxygenase-2 (COX-2) Inhibition
Current Pharmaceutical Design The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery β -[<sup>18</sup>F]Fluoro Azomycin Arabinoside (β -[<sup>18</sup>F]FAZA): Synthesis, Radiofluorination and Preliminary PET Imaging of Murine A431 Tumors
Current Radiopharmaceuticals